Lista de obras -

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

artículo científico publicado en 2015

A phantom study: Should 124 I-mIBG PET/CT replace 123 I-mIBG SPECT/CT?

artículo científico publicado en 2017

An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

scientific article published on 11 March 2020

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation

scientific article published on 24 April 2019

Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients

artículo científico publicado en 2017

Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers

artículo científico publicado en 2009

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

artículo científico publicado en 2003

Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases

scientific article published on 23 April 2012

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma

artículo científico publicado en 2009

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

artículo científico publicado en 2016

Growth of analytical thinking skills over time as measured with the MATCH test

artículo científico publicado en 2008

Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both

artículo científico publicado en 2002

Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma

artículo científico publicado en 2013

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

artículo científico publicado en 2017

Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice? ⬇️

artículo científico publicado el 22 de junio de 2012

Long-term follow-up of the thyroid gland after treatment with 131 I-Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance ⬇️

artículo científico publicado el 6 de julio de 2013

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis

artículo científico publicado en 2014

MIBG scintigraphy and PET imaging for diagnosing neuroblastoma

artículo científico publicado en 2011

Meta-iodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-288-11 and erythroleukaemic cell line HEL ⬇️

artículo científico publicado el 1 de enero de 1995

Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.

artículo científico publicado en 2011

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

artículo científico publicado en 2015

Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study

artículo científico publicado en 2020

Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors

artículo científico publicado en 2015

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

artículo científico publicado en 2017

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients

artículo científico publicado en 2016

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

scientific article published on 17 November 2019

PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma

artículo científico publicado en 2008

Peripheral stem cell apheresis is feasible post Iodine-metaiodobenzylguanidine- therapy in high-risk neuroblastoma, but results in delayed platelet reconstitution

artículo científico publicado en 2018

Plasma free metanephrines for diagnosis of neuroblastoma patients

scientific article published on 26 February 2019

Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.

artículo científico publicado en 2008

Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma

artículo científico publicado en 2019

Promising effects of the 4HPR-BSO combination in neuroblastoma monolayers and spheroids

artículo científico publicado en 2011

Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

artículo científico publicado en 2018

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. ⬇️

artículo científico publicado en 2016

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

artículo científico publicado en 2015

Response to teszler

artículo científico publicado en 2012

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

artículo científico publicado en 2020

Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.

artículo científico publicado en 2012

Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids

artículo científico publicado en 2011

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors

artículo científico publicado en 2015

The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma ⬇️

artículo científico publicado el 21 de marzo de 2011

The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma

artículo científico publicado en 2013

Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

artículo científico publicado en 2013

Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review

artículo científico publicado en 2017

Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan

artículo científico publicado en 2015

Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma

scholarly article by Esther M. van Wezel et al published January 2015 in The Journal of Molecular Diagnostics

Lista de obras de

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma

A phantom study: Should 124 I-mIBG PET/CT replace 123 I-mIBG SPECT/CT?

An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity

Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation

Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients

Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers

Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.

Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma

Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study

Growth of analytical thinking skills over time as measured with the MATCH test

Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both

Iodine-131-meta-iodobenzylguanidine therapy for patients with high-risk neuroblastoma

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may &gt;95 % tumour resection suffice? ⬇️

Long-term follow-up of the thyroid gland after treatment with 131 I-Metaiodobenzylguanidine in children with neuroblastoma: Importance of continuous surveillance ⬇️

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis

MIBG scintigraphy and PET imaging for diagnosing neuroblastoma

Meta-iodobenzylguanidine uptake in platelets, megakaryoblastic leukaemia cell lines MKPL-1 and CHRF-288-11 and erythroleukaemic cell line HEL ⬇️

Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.

Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study

Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors

Neuroblastoma is composed of two super-enhancer-associated differentiation states.

Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients

Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease

PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma

Peripheral stem cell apheresis is feasible post Iodine-metaiodobenzylguanidine- therapy in high-risk neuroblastoma, but results in delayed platelet reconstitution

Plasma free metanephrines for diagnosis of neuroblastoma patients

Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.

Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma

Promising effects of the 4HPR-BSO combination in neuroblastoma monolayers and spheroids

Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. ⬇️

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

Response to teszler

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.

Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors

The prognostic value of fast molecular response of marrow disease in patients aged over 1year with stage 4 neuroblastoma ⬇️

The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma

Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review

Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan

Whole-Genome Sequencing Identifies Patient-Specific DNA Minimal Residual Disease Markers in Neuroblastoma

Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice? ⬇️